107 related articles for article (PubMed ID: 1568412)
1. Selected monoclonal antibodies can increase the accuracy of cytodiagnosis of neoplastic effusions of cryptic origin expanded in a short term culture.
Mottolese M; Cianciulli A; Venturo I; Perrone Donnorso R; Salzano M; Benevolo M; Bigotti G; Natali PG
Diagn Cytopathol; 1992; 8(2):153-60. PubMed ID: 1568412
[TBL] [Abstract][Full Text] [Related]
2. Use of selected combinations of monoclonal antibodies to tumor associated antigens in the diagnosis of neoplastic effusions of unknown origin.
Mottolese M; Venturo I; Donnorso RP; Curcio CG; Rinaldi M; Natali PG
Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1277-84. PubMed ID: 3053205
[TBL] [Abstract][Full Text] [Related]
3. Immunocytochemical staining with monoclonal antibodies in cytologically "negative" serous effusions from patients with malignant disease.
Ghosh AK; Mason DY; Spriggs AI
J Clin Pathol; 1983 Oct; 36(10):1150-3. PubMed ID: 6194182
[TBL] [Abstract][Full Text] [Related]
4. Immunocytological analysis of the Tn associated antigen 83D4 in serous effusions from patients with cancer: comparison with Tn soluble glycoprotein.
Beuzelin-Yvraut M; Bourguignat A; Phillips E; Roseto A; Osinaga E
J Clin Pathol; 1995 May; 48(5):433-7. PubMed ID: 7629290
[TBL] [Abstract][Full Text] [Related]
5. Identification of carcinoma cells in ascitic and pleural fluid. Comparison of four panepithelial antigens with carcinoembryonic antigen.
Mezger J; Stötzer O; Schilli G; Bauer S; Wilmanns W
Acta Cytol; 1992; 36(1):75-81. PubMed ID: 1546516
[TBL] [Abstract][Full Text] [Related]
6. Detection of a soluble antigen defined by monoclonal antibody 83D4 in serous effusions associated with breast carcinoma.
Osinaga E; Pancino G; Beuzelin M; Babino A; Rodriguez D; Robello C; Tiscornia A; Phillips E; Bourguignat A; Roseto A
Cancer; 1992 Apr; 69(7):1745-9. PubMed ID: 1551059
[TBL] [Abstract][Full Text] [Related]
7. [Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1].
Daste G; Berthier F; Mauduyt MA; Soleilhavoup JP
Arch Anat Cytol Pathol; 1992; 40(4):183-9. PubMed ID: 1294046
[TBL] [Abstract][Full Text] [Related]
8. AUA1: new immunocytochemical marker for detecting epithelial cells in body cavity fluids.
Kocjan G; Sweeney E; Miller KD; Bobrow L
J Clin Pathol; 1992 Apr; 45(4):358-9. PubMed ID: 1577978
[TBL] [Abstract][Full Text] [Related]
9. Identification of second malignancies on effusions and fine-needle aspirates using a panel of monoclonal antibodies.
Mottolese M; Venturo I; Rinaldi M; Lopez M; Bigotti G; Benevolo M; Natali PG
Br J Cancer; 1997; 75(4):572-8. PubMed ID: 9052413
[TBL] [Abstract][Full Text] [Related]
10. Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature.
Davidson B
Anal Cell Pathol; 2001; 23(3-4):107-28. PubMed ID: 12082292
[TBL] [Abstract][Full Text] [Related]
11. Reactivity of tumor cells in malignant effusions with a panel of monoclonal and polyclonal antibodies.
Shaw P; Buckman R; Law J; Baumal R; Marks A
Tumour Biol; 1988; 9(2-3):101-9. PubMed ID: 3041546
[TBL] [Abstract][Full Text] [Related]
12. Immunocytochemical staining of cells in pleural and peritoneal effusions with a panel of monoclonal antibodies.
Ghosh AK; Spriggs AI; Taylor-Papadimitriou J; Mason DY
J Clin Pathol; 1983 Oct; 36(10):1154-64. PubMed ID: 6194183
[TBL] [Abstract][Full Text] [Related]
13. Use of monoclonal antibody B72.3 as a marker of metastatic carcinoma cells in neoplastic effusions.
Betta PG; Pavesi M; Pastormerlo M; Tallarida F; Bellingeri D; Bocca R
Pathologica; 1991; 83(1083):99-104. PubMed ID: 1866206
[TBL] [Abstract][Full Text] [Related]
14. Use of monoclonal antibody for assessment of estrogen and progesterone receptors in malignant effusions.
Masood S
Diagn Cytopathol; 1992; 8(2):161-6. PubMed ID: 1568413
[TBL] [Abstract][Full Text] [Related]
15. [Differential diagnostic value of B72.3, Ber-EP4 and calretinin in serous effusions].
Li XJ; Pan QJ; Shen GH; Liu XY; Sun YT
Zhonghua Zhong Liu Za Zhi; 2005 Jul; 27(7):438-41. PubMed ID: 16188134
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
Afify A; Zhou H; Howell L; Paulino AF
Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
[TBL] [Abstract][Full Text] [Related]
17. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions.
Porcel JM; Vives M; Esquerda A; Salud A; Pérez B; Rodríguez-Panadero F
Chest; 2004 Dec; 126(6):1757-63. PubMed ID: 15596670
[TBL] [Abstract][Full Text] [Related]
18. Identification of the primary site of metastatic adenocarcinoma in serous effusions. Value of an immunocytochemical panel added to the clinical arsenal.
Longatto Filho A; Alves VA; Kanamura CT; Nonogaki S; Bortolan J; Lombardo V; Bisi H
Acta Cytol; 2002; 46(4):651-8. PubMed ID: 12146025
[TBL] [Abstract][Full Text] [Related]
19. A new marker for human cancer cells. 3. Immunocytochemical detection of malignant cells in serous fluids with the Ca1 antibody.
Woods JC; Spriggs AI; Harris H; McGee JO
Lancet; 1982 Sep; 2(8297):512-4. PubMed ID: 6125677
[TBL] [Abstract][Full Text] [Related]
20. Flow cytometric identification of cancer cells in effusions with Ca1 monoclonal antibody.
Czerniak B; Papenhausen PR; Herz F; Koss LG
Cancer; 1985 Jun; 55(12):2783-8. PubMed ID: 3888371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
